Cabozantinib

(Cometriq®)

Cabozantinib

Drug updated on 12/11/2024

Dosage FormCapsule (oral; 20 mg, 80 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of 14 systematic review(s)/meta-analysis(es). [1-14]
  • Cabozantinib demonstrated prolonged progression-free survival (PFS) in radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) patients and advanced medullary thyroid cancer (aMTC) patients, showing effectiveness at both 60 mg/day and 140 mg/day dosages.
  • Lenvatinib at 18 mg/day and 24 mg/day significantly impacted PFS in RAIR-DTC, with the 18 mg/day dose achieving a hazard ratio (HR) of 0.13 for PFS.
  • Apatinib achieved a notable effect on overall survival (OS), presenting a HR of 0.42, while lenvatinib and cabozantinib also showed OS improvements in RAIR-DTC.
  • In terms of objective response rate (ORR), lenvatinib achieved the highest rate at 66%, followed by anlotinib at 59% and apatinib at 54%, with lenvatinib 18 mg/day demonstrating a favorable disease control rate (DCR) relative to other agents like sorafenib and vandetanib.
  • Cabozantinib at doses of 60 mg/day and 140 mg/day was associated with increased adverse events, with common issues being hypertension, diarrhea, and fatigue.
  • Lenvatinib demonstrated a high incidence of grade 3 or higher adverse events, particularly affecting metabolic parameters such as hypercholesterolemia and hypertriglyceridemia.
  • Vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs), including cabozantinib, presented increased cardiovascular risks, such as major adverse cardiovascular events (MACEs), heart failure, and thromboembolism.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Cometriq (cabozantinib) Prescribing Information.2023Exeltis USA, Inc., Florham Park, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis2024The Journal of Clinical Endocrinology and Metabolism
The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review2024Journal of Personalized Medicine
Efficacy and safety of tyrosine kinase inhibitors for advanced metastatic thyroid cancer: A systematic review and network meta-analysis of randomized controlled trials2024Medicine
Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis2024Journal of the Chinese Medical Association
Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature2024Endocrine
Metabolic adverse events of multitarget kinase inhibitors: a systematic review2023Endocrine
Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis2022Frontiers in Pharmacology
Cabozantinib combination therapy for the treatment of solid tumors: a systematic review2022Therapeutic Advances in Medical Oncology
Cabozantinib for the treatment of solid tumors: a systematic review2022Therapeutic Advances in Medical Oncology
Benefits and Limitations of TKIs in Patients with Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis2021European Thyroid Journal
Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis2020Endocrine Journal
Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials2020Expert Review of Clinical Pharmacology
A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick?2020Anti-Cancer Drugs
Anti-Tumor Activity and Safety of Multikinase Inhibitors in Advanced and/or Metastatic Thyroid Cancer: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials2020Hormone and Metabolic Research

Clinical Practice Guidelines